

CURRICULUM VITAE

Name:												
Peter Johnson												
Summary:												
<p>Professor of Medical Oncology at the University of Southampton Trained in Medical Oncology at St Bartholomew's Hospital in London and was Senior Lecturer in the Cancer Centre at Leeds.</p> <p>Research interests in applied immunology and immunotherapy, lymphoma biology and clinical trials. Chief Investigator for lymphoma trials ranging from first in man novel antibody therapeutics to international randomised studies, and for the Cancer Research UK Stratified Medicine Programme. Leading the Grail-NHS collaboration on blood borne markers for early cancer detection and the NHS Cancer Vaccines Launchpad.</p>												
Qualifications:												
<table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 30%;">F Med. Sci.</td> <td style="width: 40%;">London</td> <td style="width: 30%;">2014</td> </tr> <tr> <td>FRCP</td> <td>London</td> <td>1998</td> </tr> <tr> <td>MD</td> <td>University of Cambridge</td> <td>1994</td> </tr> <tr> <td>MB B.Chir</td> <td>University of Cambridge</td> <td>1985</td> </tr> </table>	F Med. Sci.	London	2014	FRCP	London	1998	MD	University of Cambridge	1994	MB B.Chir	University of Cambridge	1985
F Med. Sci.	London	2014										
FRCP	London	1998										
MD	University of Cambridge	1994										
MB B.Chir	University of Cambridge	1985										
Present Posts:												
<p>From August 1998: Professor of Medical Oncology, University of Southampton Faculty of Medicine. Honorary Consultant in Medical Oncology, Southampton University Hospitals NHS Trust.</p> <p>From October 2019: National Clinical Director for Cancer, NHS England</p> <p>From June 2023: Chair, Cancer Mission, UK Government Office for Life Sciences</p>												
Recent Posts:												
<p>Jan 2008-Oct 2017: Chief Clinician – Cancer Research UK Apr 1994-Jul 1998: Senior Lecturer in Medical Oncology – University of Leeds Aug 1989-Mar 1994: ICRF Clinical Research Fellow – St Bartholomew's Hospital, London</p>												
National/International committees:												
<ul style="list-style-type: none"> • National Cancer Research Institute, Board 2008-2015, Trustee 2015-2017 • Academy of Medical Sciences Review of Research Governance and Regulation 2010-2011 • NHS Chief Executive Review of Innovation: External Advisory Group 2011 • Cancer Immunotherapy (CIMT) Consortium, Executive Board 2008-2015 • Genomics England Ltd Scientific Advisory Committee 2013-2016 • International Conference on Malignant Lymphoma (ICML): Scientific Committee 2008- • International advisor, Schweiz. Arbeitsgemeinschaft für Klinische Krebsforschung (SAKK) 2010- • Institut Suisse de Recherche Expérimentale sur le Cancer (ISREC) Foundation Scientific Board 2015- • Royal College of Physicians Joint Specialty Committee on Medical Oncology, Chair 2018-2022 												
Academic activities:												
<p>Research Output and Dissemination:</p> <ul style="list-style-type: none"> • Over 80 invited lectures since 2010. John Ulmann memorial lecture at ICML 2023. • Over 200 peer-reviewed papers <p>Postgraduate Research Training:</p> <ul style="list-style-type: none"> • 25 PhD or MD's graduated since 2005 												
Recent publications:												

Luminari S, Fossa A, Trotman J, Molin D, et al., Long-Term Follow-Up of the Response-Adjusted Therapy for Advanced Hodgkin Lymphoma Trial. **J Clin Oncol.** 2024;42:13-18

Davies AJ, Barrans S, Stanton L, et al. Differential Efficacy From the Addition of Bortezomib to R-CHOP in Diffuse Large B-Cell Lymphoma According to the Molecular Subgroup in the REMoDL-B Study With a 5-Year Follow-Up. **J Clin Oncol.** 2023;41:2718-2723

Johnson PWM, Balasubramanian S, Hodgkinson B, et al. Clinical impact of ibrutinib plus R-CHOP in untreated DLBCL co-expressing BCL2 and MYC in the phase 3 PHOENIX trial. **Blood Adv.** 2023;7(10):2008-2017

Rodday AM, Parsons SK, Upshaw JN, et al. The Advanced-Stage Hodgkin Lymphoma International Prognostic Index: Development and Validation of a Clinical Prediction Model From the HoLISTIC Consortium. **J Clin Oncol.** 2023;41:2076-2086

Davies JR, Hilton LK, Jiang A, et al. Comparison of MHG and DZsig reveals shared biology and a core overlap group with inferior prognosis in DLBCL. **Blood Adv.** 2023; 7:6156-6162

Neal RD, Johnson P, Clarke CA, et al.. Cell-Free DNA-Based Multi-Cancer Early Detection Test in an Asymptomatic Screening Population (NHS-Galleri): Design of a Pragmatic, Prospective Randomised Controlled Trial. **Cancers** (Basel). 2022 Oct 1;14(19):4818.

Bewicke-Copley F, Korfi K, Araf S, et al., Longitudinal expression profiling identifies a poor risk subset of patients with ABC-type Diffuse Large B Cell Lymphoma. **Blood Adv.** 2023; 7:845-855

Lee LYW, Starkey T, Ionescu MC, et al., Vaccine effectiveness against COVID-19 breakthrough infections in patients with cancer (UKCCEP): a population-based test-negative case-control study. **Lancet Oncol.** 2022:S1470-2045(22)00202-9

Ferreri AJM, Cwynarski K, Pulczynski E, et al. Long-term efficacy, safety and neurotolerability of MATRix regimen followed by autologous transplant in primary CNS lymphoma: 7-year results of the IELSG32 randomized trial. IELSG32 study investigators. **Leukemia.** 2022;36(7):1870-1878

Lim SH, Stuart B, Joseph-Pietras D, et al., Immune responses against SARS-CoV-2 variants after two and three doses of vaccine in B-cell malignancies: UK PROSECO study. **Nat Cancer.** 2022 May;3(5):552-564

Hutchings M, Mous R, Clausen MR, Johnson P et al., Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1/2 study. **Lancet.** 2021;398:1157-1169.

Lim SH, Campbell N, Johnson M, et al., Antibody responses after SARS-CoV-2 vaccination in patients with lymphoma. **Lancet Haematol.** 2021;8(8):e542-e544

Heward JA, Koniali L, D'Avola A, et al., JKDM5 inhibition offers a novel therapeutic strategy for the treatment of KMT2D mutant lymphomas. **Blood.** 2021; 138(5):370-81

Clift AK, Coupland CAC, Keogh RH, et al., Living risk prediction algorithm (QCOVID) for risk of hospital admission and mortality from coronavirus 19 in adults: national derivation and validation cohort study. **BMJ.** 2020 Oct 20;371:m3731

Clark JJ, Dwyer D, Pinwill N, Clark P, Johnson P, Hackshaw A. The effect of clinical decision making for initiation of systemic anticancer treatments in response to the COVID-19 pandemic in England: a retrospective analysis. **Lancet Oncol.** 2020:S1470-2045(20)30619-7.

Cummin TEC, Cox KL, Murray TD, et al., BET inhibitors synergize with venetoclax to induce apoptosis in MYC-driven lymphomas with high BCL-2 expression. **Blood Adv.** 2020;4(14):3316-3328

Sha C, Barrans S, Cucco F, et al., Molecular High-Grade B-Cell Lymphoma: Defining a Poor-Risk Group That Requires Different Approaches to Therapy. **J Clin Oncol.** 2019;37(3):202-212

Barrington SF, Phillips EH, et al. Positron Emission Tomography Score Has Greater Prognostic Significance Than Pretreatment Risk Stratification in Early-Stage Hodgkin Lymphoma in the UK RAPID Study. **J Clin Oncol.** 2019; 37(20):1732-1741

Yap TA, Winter JN, Giulino-Roth L, et al., Phase 1 study of the novel enhancer of zeste homolog 2 (EZH2) inhibitor GSK2816126 in patients with advanced hematological and solid tumors. **Clin Cancer Res.** 2019;25(24):7331-7339

Ansell SM, Minnema MC, Johnson P, et al., Nivolumab for Relapsed/Refractory Diffuse Large B-Cell Lymphoma in Patients Ineligible for or Having Failed Autologous Transplantation: A Single-Arm, Phase II Study. **J Clin Oncol.** 2019;37(6):481-489

Younes A, Sehn LH, Johnson P, et al., Randomized Phase III Trial of Ibrutinib and Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Non-Germinal Center B-Cell Diffuse Large B-Cell Lymphoma. **J Clin Oncol.** 2019; 37(15):1285-1295

Davies A, Cummin TE, Barrans S, et al., Gene-expression profiling of bortezomib added to standard chemoimmunotherapy for diffuse large B-cell lymphoma (REM0DL-B): an open-label, randomised, phase 3 trial. **Lancet Oncol.** 2019;20(5):649-662

Drennan S, Chiodin G, D'Avola A, et al., Ibrutinib therapy releases leukemic surface IgM from antigen drive in chronic lymphocytic leukemia patients. **Clin Cancer Res.** 2019;25(8):2503-2512

Ceriani L, Milan L, Martelli M, et al., Metabolic heterogeneity on baseline 18FDG-PET/CT scan is a predictor of outcome in primary mediastinal B-cell lymphoma. **Blood** 2018; 132:179-186.

Buchan SL, Dou L, Remer M, et al., Antibodies to Costimulatory Receptor 4-1BB Enhance Anti-tumor Immunity via T Regulatory Cell Depletion and Promotion of CD8 T Cell Effector Function. **Immunity.** 2018;49(5):958-970.e7